You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 10, 2024

~ Buy the NATROBA (spinosad) Drug Profile, 2024 PDF Report in the Report Store ~

NATROBA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Natroba patents expire, and what generic alternatives are available?

Natroba is a drug marketed by Cipher and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the spinosad profile page.

DrugPatentWatch® Generic Entry Outlook for Natroba

Natroba was eligible for patent challenges on January 18, 2015.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NATROBA?
  • What are the global sales for NATROBA?
  • What is Average Wholesale Price for NATROBA?
Drug patent expirations by year for NATROBA
Drug Prices for NATROBA

See drug prices for NATROBA

Drug Sales Revenue Trends for NATROBA

See drug sales revenues for NATROBA

Recent Clinical Trials for NATROBA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medpace, Inc.Phase 4
STATKING Clinical ServicesPhase 4
Inotiv LaboratoriesPhase 4

See all NATROBA clinical trials

Pharmacology for NATROBA
Drug ClassPediculicide

US Patents and Regulatory Information for NATROBA

NATROBA is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting NATROBA

Methods and compositions useful for controlling cutaneous mites
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED

FDA Regulatory Exclusivity protecting NATROBA

FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATROBA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Sign Up ⤷  Sign Up
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Sign Up ⤷  Sign Up
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Sign Up ⤷  Sign Up
Cipher NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for NATROBA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Elanco GmbH Comfortis spinosad EMEA/V/C/002233
Treatment and prevention of flea infestations (Ctenocephalides felis).The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Withdrawn no no no 2011-02-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for NATROBA

See the table below for patents covering NATROBA around the world.

Country Patent Number Title Estimated Expiration
Denmark 642089 ⤷  Sign Up
Australia 624458 ⤷  Sign Up
Spain 2075112 ⤷  Sign Up
Romania 106065 COMPUSI MACROLIDICI CU ACTIVITATE INSECTICIDA SI MITICIDA SI PROCEDEU DE PREPARARE A LOR (MACROLIQUIDIC COMPOUNDS WITH INSECTICIDE AND MITICIDE ACTIVITY AND PREPARATION PROCESS THEREFOR) ⤷  Sign Up
Morocco 21697 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NATROBA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0375316 06C0047 France ⤷  Sign Up PRODUCT NAME: SPINOSAD; REGISTRATION NO/DATE IN FRANCE: 2060098 DU 20060628; REGISTRATION NO/DATE AT EEC: 9275/B DU 20011023
0375316 C350009 Netherlands ⤷  Sign Up PRODUCT NAME: SPINOSAD, DESGEWENST IN DE VORM VAN EEN ZOUT; NATL. REGISTRATION NO/DATE: 12363 N 20020913; FIRST REGISTRATION: SE 4511 20020204
0375316 SPC/GB02/028 United Kingdom ⤷  Sign Up PRODUCT NAME: SPINOSAD; REGISTERED: CH W 6020 20010313; UK 0714 20020227
0375316 350009 Netherlands ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.